NAS:DMAC Key Ratios
| Market Cap $ M | 351.06 |
| Enterprise Value $ M | 307.74 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 9.16 |
| Price/Sales | -- |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -0.72 |
| Beneish M-Score | 0 |
| 10-y EBITDA Growth Rate % | -2.50 |
| 5-y EBITDA Growth Rate % | 0.60 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -7.85 |
| EV-to-EBITDA | -7.86 |
| PEG | -- |
| Shares Outstanding M | 53.93 |
| Net Margin (%) | -- |
| Operating Margin % | -- |
| Pre-tax Margin (%) | -- |
| Quick Ratio | 6.72 |
| Current Ratio | 6.72 |
| ROA % (ttm) | -75.70 |
| ROE % (ttm) | -85.14 |
| ROIC % (ttm) | -2,239.95 |
| Dividend Yield % | -- |
| Altman Z-Score | -- |
DMAC Number of Guru Trades
DMAC Volume of Guru Trades
Gurus Latest Trades with NAS:DMAC
NAS:DMAC is held by these investors
DiaMedica Therapeutics Inc Insider Transactions
Guru Commentaries on NAS:DMAC
DiaMedica Therapeutics (DMAC) presents a compelling investment opportunity due to its innovative DM199 therapy, which targets critical blood flow issues in stroke and preeclampsia. The company has a strong foundation with promising clinical data, including a Phase 2 trial that shows significant improvement in non-MT stroke patients. The potential market for stroke treatment is estimated at $10 billion, while preeclampsia represents a $5 billion opportunity. DMAC's unique recombinant KLK1 protein can be produced to high standards without human sourcing, enhancing its appeal. With a solid cash position and no debt, DMAC is well-positioned for upcoming clinical milestones, making it an attractive addition to our portfolio.
News about NAS:DMAC
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
